Iovance Biotherapeutics, Inc. (IOVA) — Analyst outlook / Analyst consensus target is. Based on 20 analyst ratings, the consensus is bullish — 15 Buy, 5 Hold.
The consensus price target is $2.00, representing a downside of 45.1% from the current price $3.64.
Analysts estimate Earnings Per Share (EPS) of $-1.29 and revenue of $0.16B for the next fiscal year.
Earnings Per Share (EPS) track record: 2024: actual $-1.28 vs est $-1.29 (beat +1.1%). 2025: actual $-1.09 vs est $-1.08 (missed -1%). Analyst accuracy: 99%.
IOVA Stock — 12-Month Price Forecast
$2.00
▼ -45.05% Downside
Average Price Target
Based on 20 Wall Street analysts offering 12-month price targets for Iovance Biotherapeutics, Inc., the price target is $2.00.
The average price target represents a -45.05% change from the last price of $3.64.
IOVA Analyst Ratings
Buy
Based on 20 analysts giving stock ratings to Iovance Biotherapeutics, Inc. in the past 3 months
EPS Estimates — IOVA
99%
Analyst Accuracy
Accurate
2 years compared
Actual vs Estimate
2024
Actual –$1.28
vs Est –$1.29
▲ 1.2% off
2025
Actual –$1.09
vs Est –$1.08
▼ 1.0% off
Profitability Outlook
Company has been making losses in all recent fiscal years. EPS is improving but still negative. Analysts expect losses to continue near-term.
Revenue Estimates — IOVA
98%
Analyst Accuracy
Accurate
2 years compared
Actual vs Estimate
2024
Actual $0.164B
vs Est $0.162B
▲ 1.0% off
2025
Actual $0.264B
vs Est $0.258B
▲ 2.2% off
Revenue Trend
Strong revenue growth over the period shown. Analysts forecast revenue contraction ahead.
